The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt ...
The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt ...
BridgeBio Pharma plans to offer $500 million in convertible senior notes, aiming to strengthen its financial position and reduce interest expenses. BridgeBio Pharma, Inc. announced plans to offer $500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results